Internal Medicine Unit, Edéa Regional Hospital, Edéa, Cameroon.
J Infect Public Health. 2014 Sep-Oct;7(5):407-12. doi: 10.1016/j.jiph.2014.04.007. Epub 2014 Jun 2.
Severe malaria kills more than a half million people each year. Based on high-quality evidence of the efficacy superiority of artesunate over quinine in adults and children with severe malaria, the World Health Organization guidelines have been revised. The WHO currently recommends injectable artesunate as the first-line treatment for severe malaria. Since this revision in April 2011, only a small number of countries affected by malaria have adopted and implemented the new policy. If this policy is implemented, an additional 195,000 lives would be saved each year in Africa. Thus, there is an urgent need to speed up access to injectable artesunate in malaria-endemic countries. This review presents a background for recommending artesunate as the first-line treatment of severe malaria in children and adults, and interventions that are recommended to accelerate access to injectable artesunate.
每年有超过 50 万人死于重症疟疾。基于青蒿琥酯在成人和儿童重症疟疾中的疗效优于奎宁的高质量证据，世界卫生组织的指南已经修订。世卫组织目前建议将注射用青蒿琥酯作为重症疟疾的一线治疗药物。自 2011 年 4 月修订以来，只有少数疟疾流行国家采取并实施了新政策。如果实施这一政策，非洲每年将额外挽救 19.5 万人的生命。因此，迫切需要加快在疟疾流行国家获得注射用青蒿琥酯。这篇综述为推荐青蒿琥酯作为儿童和成人重症疟疾的一线治疗药物以及推荐加速获得注射用青蒿琥酯的干预措施提供了背景。
